Gritstone bio Reports First Quarter 2024 Financial Results and ...

united states securities and exchange commission - Gritstone bio

Date of Report (Date of earliest event ... financial results and business operations. These and other factors that may affect the Company's future business ...

Press Releases - Gritstone bio

... Results from GRANITE Phase 1/2 Study and Poster at SITC 2022. November 10, 2022. Gritstone Reports Third Quarter 2022 Financial ... 2024 Gritstone Bio |. Footer ...

Press Releases - Gritstone bio

... Reports Second Quarter 2021 Financial Results and Business Update. August 5, 2021. Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4 ...

Form 8-K for Gritstone BIO INC filed 02/12/2024

Date of Report (Date of earliest event reported): February 12, 2024 ... between now and the time the financial results for this period are finalized, and ...

Press Releases | Gritstone bio

... Annual Healthcare Conference. November 26, 2019. Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights. November 12, 2019.

Press Releases | Gritstone bio

... Reports Third Quarter Financial Results and Recent Highlights. November 5, 2020. Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its ...

Gritstone Oncology to Webcast Investor Event Reviewing its ...

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer ...

Gritstone Oncology, Inc.

... financial statements included in quarterly reports on Form 10-Q. The ... We dosed our first patient in the first quarter of 2019. The Phase 1 portion ...

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial ...

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates ; Collaboration and license revenues, $ ...

Gritstone bio Awarded BARDA Contract to Conduct Comparative ...

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at ...

Gritstone Reports Second Quarter 2022 Financial Results and ...

Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update · Durable neutralizing antibodies against wild type Spike as ...

Gritstone Oncology, Inc.

Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's financial statements as of and ...

Gritstone bio Announces Positive Preliminary Progression-free ...

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of ...

BREAK THROUGHS - Gritstone bio

BARDA in the Fall of 2024 rather than first quarter of 2024. This is ... report our results of operations and financial statements on ...

Gritstone Reports Third Quarter 2021 Financial Results and ...

Gritstone Reports Third Quarter 2021 Financial Results and Business Update · Cash, cash equivalents. · Research and development expenses were ...

Gritstone bio Reports Third Quarter 2023 Financial Results and ...

initiated in the first quarter of 2024. In October 2023, new data was presented from Gritstone's three Phase 1 CORAL studies. Results across ...

Gritstone Reports Fourth Quarter and Full Year 2020 Financial ...

Gritstone Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights · $22.8 million for the three months ended December 31, 2020 , and ...

Gritstone Reports Third Quarter 2022 Financial Results and ...

2022 ; Assets. Current assets: ; Current assets: Cash and cash equivalents ; Cash and cash equivalents, $, 64,909 ; Marketable securities, 74,900 ...

Form 8-K for Gritstone BIO INC filed 08/09/2023

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates. -- ... first quarter of 2024.” Dr. Allen con ...

Gritstone bio Announces Workforce Reduction

29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most ...